{"name":"Biodesix","slug":"biodesix","ticker":"BDSX","exchange":"NASDAQ","domain":"biodesix.com","description":"Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic ","hq":"Boulder, CO","founded":0,"employees":"334","ceo":"Scott Hutton","sector":"Diagnostics / Lung Cancer","stockPrice":14.53,"stockChange":-0.11,"stockChangePercent":-0.75,"marketCap":"$147M","metrics":{"revenue":88499000,"revenueGrowth":40.8,"grossMargin":81.1,"rdSpend":12001000,"netIncome":-35265000,"cash":18987000,"dividendYield":0,"peRatio":-66,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Biodesix Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Biodesix reported revenue of $24.4 million for the fourth quarter and $93.8 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Biodesix Announces Collaboration with Pfizer to Develop Companion Diagnostic for Pfizer's Lung Cancer Treatment","summary":"Biodesix will develop a companion diagnostic for Pfizer's lung cancer treatment, which is currently in Phase 3 clinical trials.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"Biodesix Receives FDA Clearance for Nodify XL2 Test","summary":"The Nodify XL2 test is a liquid biopsy test for lung cancer that uses a combination of biomarkers to detect the presence of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOWi0tM3NTdnVnTGhmWC12LVRyejJhVGtHSDhIeHZwZzhxcDhfeGg5YTFBaGY2NkJfOFE3eGhzY2MyeW1GYWJKa1Ewa1NGLVZuVmZwSVhCZWhnV2pUbUVNSUdaeFJld19qY1Z6bFpZQWJtNVNyRHhSZnRCZ29Jc1l4d1pTTXA0VTd2Sml5ZUg4bXJzQWxhSlhKbHZwdC0yYlpEZzFRZUhibmFhaVU3M3lyRDIxa09VQQ?oc=5","date":"2026-04-06","type":"pipeline","source":"TradingView","summary":"Revvity Gains on Diagnostics Strength, Faces China Headwinds - TradingView","headline":"Revvity Gains on Diagnostics Strength, Faces China Headwinds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPdWs1bjdMSFZMY0I1RjlpMzJ4WVBXVHlUV0hqNDI3UEEtMDh2NGYwYW1UWW5mTjZuU29lNXlqTWNqQWxDbFZLTm9JSkpUNEFkSE9WemFFSGItY0ZyTHA4NG1Hd1k4SWMyU3F0T2xVOWNjVmh1X19pRWNfa19qZmdkLWNESWFGTXd2T1hJZjladWFHTjQxTW12VzhmNFptNHo5cGFhMUpweVV1QQ?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"Biodesix (BDSX) chair adds 1,361 shares through RSU exercise - Stock Titan","headline":"Biodesix (BDSX) chair adds 1,361 shares through RSU exercise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNTks0eElpM1dlOF9CVmN4akZmaUppSURWOEhNQVhyNGEwVE5BeFhUM3hCMnhLRmhTUXNWV2R6ZmtXcTVpSGNzVWl4M0FVdXRwMkpHSHpFblhKVUhUV0UtWXBLcXZ5UmJsN1E4LUFDalpLVHZiTTVmT0dYdzZtN3dGaDA5ZllrUHVNNzlqUm85TjYxZ0x2RHNkQWtpOENDaEZReU9fbmRVUmE2TVZxQzhr?oc=5","date":"2026-03-30","type":"pipeline","source":"MarketBeat","summary":"Biodesix, Inc. (NASDAQ:BDSX) Short Interest Down 19.4% in March - MarketBeat","headline":"Biodesix, Inc. (NASDAQ:BDSX) Short Interest Down 19.4% in March","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1qdE1CQ2F6LWVvRjVfekJBb19KSzl6Sm9DWmx1M2c3V09aX0J6RFplaDlZek5VUk9YeWg4RGxidW5qbWZJdWJ0M1NiU3NZQjVIeFV5M25RNHFOSlB0bGfSAWNBVV95cUxNbmxkWmk5MUREODFUa2dBelVQa3VZTGZjUjBJZF9HaDltOUlvQnBxZ1prd2pjbFRVOV9rc0pPZ3B2a2Y5NVFtQ1dYdkdiS01wd3BsLWhUSEt0eUZSUEJxa3RyZ0E?oc=5","date":"2026-03-19","type":"pipeline","source":"Bitget","summary":"Is Biodesix (BDSX) Shares Surpassing Other Medical Stocks This Year? - Bitget","headline":"Is Biodesix (BDSX) Shares Surpassing Other Medical Stocks This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQallTbnZTdFQzMDVkVGUxSk84d0V0SEZ2VHI0WHhsNks3dTdJdl9JaFhpZ0czWVI3VFlDVWFJZjhFVEowTFllM1JJWE1Tc1luaWtpLTRmRWUtaVBtbXo4UEVOemFRU0VqbTJLRkJPSWtSOVR6aDZNX0tydW5nTFAxQm1peUpTU2ctVWVCbEo0eUFZQlM5TkZDalVXQzdzU2taNHlOU2kwc0xOd2Rka0RPLXEwNDY?oc=5","date":"2026-03-03","type":"pipeline","source":"Investing.com","summary":"Biodesix at TD Cowen Conference: Lung Diagnostics Expansion - Investing.com","headline":"Biodesix at TD Cowen Conference: Lung Diagnostics Expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOOC0yYjhSOGZwamVsbTg0OGhJT0NYMHZwdDk5Z1MzWV82aDI3bmtZZjB4REI5U2FoX2d1U2NTejdmX0pIelpXUml3bUJpSkFyX2lDOWtMOUViZml0dUE1ZjZJQ214eWViZmlUUFRvX1JaSm9ua0RFVmNNYi1zUDk1eTdUemR4dk5VREVSd3k0c1p1WFhneUFJQ2ZUcWVEY0R0ZWFpZzJENE14c1VHSGYtREp4cW96U0tnanVxUTBR?oc=5","date":"2026-02-26","type":"pipeline","source":"Stock Titan","summary":"Lung test maker Biodesix beats 2025 guidance, targets 23% growth - Stock Titan","headline":"Lung test maker Biodesix beats 2025 guidance, targets 23% growth","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaTBCd0F6RnA5UnU5a2lJVURRN3dxNkVHRzg4VFkwTGE3TWRQYkFVeWJIZmZyWEFObkdOTk1ad1Zyckx1aWtuWHVUbjNKeVRZVW9fWEFqbTQxS2Zuekc1RGxNbkl3Tm41X3pXRkhFYVVRZDFOU3VUWGUyS3RxOWQ3aUF5d19rZFdZMmdib0pPek83ZVBTLTZCWFFIMEdFcVRwdGFKdHZraHRlS09WWmphTkhoeDVIdERpeXdR?oc=5","date":"2026-01-12","type":"earnings","source":"Stock Titan","summary":"Lung cancer testing helps Biodesix lift Q4 2025 revenue by 41% - Stock Titan","headline":"Lung cancer testing helps Biodesix lift Q4 2025 revenue by 41%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE1EbHpOTkVseTlhd09LZnlhdHlzR3g2N1RrdFpqd3I5Rjd2ZktQd2luNWJlOHZUSTF4NUxtbUljZk5Yc0Q2dDEyR3VJZDJjQQ?oc=5","date":"2026-01-12","type":"pipeline","source":"StocksToTrade","summary":"Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade","headline":"Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9zR2VrQVlUOXlrSWpsZ0pWNzk2Z3dHZGtyaHVrR3Rfa1dJZEtmeXpFY1NQZzU4NmFLUWR2c0FhTlV0OERWUWNFZHI4dDFRd052eEx3Zm5IVkx2LWNDOG8zRWVsZVFLcWRGVFk4MjRhem9DckJsVTlr?oc=5","date":"2026-01-12","type":"pipeline","source":"timothysykes.com","summary":"Biodesix Stock Rebounds on Strategic Plans for Market Expansion - timothysykes.com","headline":"Biodesix Stock Rebounds on Strategic Plans for Market Expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQNnFtUEhfREYyZmVlTWxUVHI4ZmdxbG5mdS1WYXVseWtsSWtEWUd5V2NnLWc3Z0FyMWU3XzFpSFhiRTBpb0RvSnVfSjdKaGRhWGIwWWpmSjJ1SmdsMVJUeEpRYjRISUpEM1lKOFJZOWJwanZzdnFObUxXeVVmYmlYTV9tUTZfajdaSU9LSGVlLWhaV09wcUN1NFJvSkpnbzF2dmxySjRJcUh3Z0lZYVdUS2ZTaHhWVlB2UHQ3dFc2bGZiTDA?oc=5","date":"2025-09-11","type":"pipeline","source":"GlobeNewswire","summary":"Biodesix Announces One-for-Twenty Reverse Stock Split - GlobeNewswire","headline":"Biodesix Announces One-for-Twenty Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQamd6OFlCOUgwUnpfSmtFa1RUejd1Z1Q0YzdUWndiY0NBMEVKT2Uyd0RoMnVUdmh5WHNvV0VfOV9Cd3I0Z1NMZmdiYk5UdzByVjEwVTZGOTJPM041T1lBMmFtTnFEUjBFZlNpcDUxSGtEWV91TDdFMWR2TVdOMEJaVQ?oc=5","date":"2025-03-04","type":"deal","source":"Yahoo Finance","summary":"Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025 - Yahoo Finance","headline":"Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1uUHA5MUNSM2dTMUFEc2V2M19ScW5rMy0wSjNNZEZhaklnRWxvLUdqLWozcmZRa0JtRVJ6OHA1andaM2RHTVQ5T1g2U3dNN2E0?oc=5","date":"2024-01-31","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Foundation Medicine","Invitae","Exact Sciences"],"therapeuticFocus":["Lung Cancer"],"financials":{"source":"sec_edgar+yahoo","revenue":88499000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":88499000,"period":"2025-12-31"},{"value":71323000,"period":"2024-12-31"},{"value":71323000,"period":"2024-12-31"},{"value":49087000,"period":"2023-12-31"},{"value":49087000,"period":"2023-12-31"}],"grossProfit":71780000,"grossProfitHistory":[{"period":"2025-12-31","value":71780000},{"period":"2024-12-31","value":55750000},{"period":"2023-12-31","value":36077000},{"period":"2022-12-31","value":24058000}],"rdSpend":12001000,"rdSpendHistory":[{"period":"2025-12-31","value":12001000},{"period":"2024-12-31","value":9559000},{"period":"2023-12-31","value":9988000},{"period":"2022-12-31","value":13102000}],"sgaSpend":87545000,"operatingIncome":-27766000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-27766000},{"period":"2024-12-31","value":-34260000},{"period":"2023-12-31","value":-41298000},{"period":"2022-12-31","value":-50506000}],"netIncome":-35265000,"netIncomeHistory":[{"period":"2025-12-31","value":-35265000},{"period":"2024-12-31","value":-42931000},{"period":"2023-12-31","value":-52146000},{"period":"2022-12-31","value":-65447000}],"eps":-4.67,"epsHistory":[{"period":"2025-12-31","value":-4.67},{"period":"2024-12-31","value":-6.6},{"period":"2023-12-31","value":-12.8},{"period":"2022-12-31","value":-31}],"cash":18987000,"cashHistory":[{"period":"2025-12-31","value":18987000},{"period":"2024-12-31","value":26245000},{"period":"2023-12-31","value":26284000},{"period":"2022-12-31","value":43088000}],"totalAssets":87476000,"totalLiabilities":89941000,"totalDebt":72854000,"equity":-2465000,"operatingCashflow":-23271000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-23271000},{"period":"2024-12-31","value":-48649000},{"period":"2023-12-31","value":-22870000},{"period":"2022-12-31","value":-44972000}],"capex":-403000,"capexHistory":[{"period":"2025-12-31","value":-403000},{"period":"2024-12-31","value":-3440000},{"period":"2023-12-31","value":-23062000},{"period":"2022-12-31","value":-3534000}],"freeCashflow":-23674000,"dividendsPaid":null,"buybacks":null,"employees":334,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":24261000,"ebit":-5816000,"ebitda":-4401000,"period":"2026-03-31","revenue":25555000,"epsBasic":-0.81,"netIncome":-7793000,"rdExpense":3285000,"epsDiluted":-0.81,"grossProfit":21350000,"operatingIncome":-6196000},{"sga":22972000,"ebit":-1921000,"ebitda":-515000,"period":"2025-12-31","revenue":28755000,"epsBasic":-0.49,"netIncome":-3980000,"rdExpense":2870000,"epsDiluted":-0.49,"grossProfit":23876000,"operatingIncome":-1966000},{"sga":21714000,"ebit":-6642000,"ebitda":-5264000,"period":"2025-09-30","revenue":21768000,"epsBasic":-1.16,"netIncome":-8716000,"rdExpense":2992000,"epsDiluted":-1.16,"grossProfit":17662000,"operatingIncome":-7044000},{"sga":22411000,"ebit":-9570000,"ebitda":-8158000,"period":"2025-06-30","revenue":20018000,"epsBasic":-1.6,"netIncome":-11468000,"rdExpense":3269000,"epsDiluted":-1.6,"grossProfit":15987000,"operatingIncome":-9693000},{"sga":20448000,"ebit":-9416000,"ebitda":-8011000,"period":"2025-03-31","revenue":17958000,"epsBasic":-1.52,"netIncome":-11101000,"rdExpense":2870000,"epsDiluted":-1.52,"grossProfit":14255000,"operatingIncome":-9063000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.53,"previousClose":14.64,"fiftyTwoWeekHigh":20.21,"fiftyTwoWeekLow":3.44,"fiftyTwoWeekRange":"3.44 - 20.21","fiftyDayAverage":14.43,"twoHundredDayAverage":9.94,"beta":0.42,"enterpriseValue":167143696,"forwardPE":-66,"priceToBook":-48.6,"priceToSales":1.66,"enterpriseToRevenue":1.89,"enterpriseToEbitda":-7.56,"pegRatio":0,"ebitda":-22096000,"ebitdaMargin":-25,"freeCashflow":-11825250,"operatingCashflow":-23271000,"totalDebt":75027000,"debtToEquity":0,"currentRatio":1.86,"returnOnAssets":-18.8,"returnOnEquity":-383.1,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":30.5,"targetHighPrice":40,"targetLowPrice":22,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":43.1,"institutionHeldPercent":29.6,"sharesOutstanding":10108580,"floatShares":5209452,"sharesShort":174016,"shortRatio":2.55,"shortPercentOfFloat":1.7,"epsTrailing":-3.96,"epsForward":-0.22,"revenuePerShare":11.72,"bookValue":-0.3,"officers":[{"age":53,"name":"Mr. Scott  Hutton","title":"President, CEO & Director"},{"age":45,"name":"Ms. Robin Harper Cowie","title":"CFO, Secretary & Treasurer"},{"age":47,"name":"Mr. Kieran  O'Kane","title":"Chief Commercial Officer"},{"age":null,"name":"Dr. Heinrich  Roder D.Phil","title":"Founder & CTO"},{"age":57,"name":"Dr. Gary Anthony Pestano Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Jessica  Olbricht","title":"Senior Director of Human Resources"},{"age":null,"name":"Ms. Bobbi  Coffin","title":"Chief Growth Officer"},{"age":null,"name":"Dr. James R. Jett M.D.","title":"Co-Chief Medical Officer"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.biodesix.com","phone":"303 417 0500"}}